A PSA test is a common way to screen for prostate cancer. While a single PSA reading may signal prostate trouble, repeated measurements of PSA may offer a more precise means of detection.

Prostate tumors can often be controlled by hormone-blocking drugs, but they may become resistant after a few years. A molecular switch could offer a new means for cancer control.

Men who like to flaunt those muscles at the gym may have another reason to keep fit and active besides looking good and feeling strong.

To treat potentially deadly prostate cancer, the surgical removal of the prostate is sometimes necessary. The procedure can have potential side effects, including a shortened penis.

High levels of certain proteins appear to stimulate tumor growth. Newly discovered proteins can help doctors identify patients who are at increased risk for aggressive prostate cancer.

Most prostate cancers are fed by male hormones called androgens. So treating the disease often involves blocking these hormones. It’s called androgen deprivation therapy (ADT), and it’s been used for decades – but not without controversy.

Zytiga ( abiraterone acetate) received expanded use approval to treat men with advanced prostate cancer last week. In addition to extending lives, a new study has found Zytiga also keeps men feeling better during their journey.

Men with metastatic prostate cancer may have a new treatment.  Radium-223 dichloride (radium-223) is designed to treat castration-resistant prostate cancer that has spread to the bone.

Patients with advanced prostate cancer may have cancer cells that spread to the bone and cause pain. A new drug shows promise by rapidly reducing prostate cancer bone tumors.

Men with castration-resistant prostate cancer have another treatment option. The US Food and Drug Administration (FDA) has approved the expanded use of Zytiga (abiraterone acetate).